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Thr 163 Phosphorylation Causes Mcl-1 Stabilization
when Degradation Is Independent of the Adjacent GSK3Targeted Phosphodegron, Promoting Drug Resistance in
Cancer
Shanna K. Nifoussi1,2., Julie A. Vrana.¤a, Aaron M. Domina¤b, Alfredo De Biasio¤c, Jingang Gui¤d,
Mark A. Gregory¤e, Stephen R. Hann3, Ruth W. Craig1,2*
1 Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America, 2 Norris Cotton Cancer
Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States of America, 3 Department of Cell and Developmental Biology, Vanderbilt University
School of Medicine, Nashville, Tennessee, United States of America

Abstract
The antiapoptotic Bcl-2 family member Mcl-1 is a PEST protein (containing sequences enriched in proline, glutamic acid,
serine, and threonine) and is subject to rapid degradation via multiple pathways. Impaired degradation leading to the
maintenance of Mcl-1 expression is an important determinant of drug resistance in cancer. Phosphorylation at Thr 163 in
the PEST region, stimulated by 12-O-tetradecanoylphorbol acetic acid (TPA)-induced activation of extracellular signalregulated kinase (ERK), is associated with Mcl-1 stabilization in BL41-3 Burkitt lymphoma cells. This contrasts with the
observation that Thr 163 phosphorylation in normal fibroblasts primes glycogen synthase kinase (GSK3)-induced
phosphorylation at Ser 159, producing a phosphodegron that targets Mcl-1 for degradation. In the present follow-up
studies in BL41-3 cells, Mcl-1 degradation was found to be independent of the GSK3-mediated pathway, providing a parallel
to emerging findings showing that Mcl-1 degradation through this pathway is lost in many different types of cancer.
Findings in Mcl-1-transfected CHO cells corroborated those in BL41-3 cells in that the GSK3-targeted phosphodegron did
not play a major role in Mcl-1 degradation, and a phosphomimetic T163E mutation resulted in marked Mcl-1 stabilization.
TPA-treated BL41-3 cells, in addition to exhibiting Thr 163 phosphorylation and Mcl-1 stabilization, exhibited an ,10-fold
increase in resistance to multiple chemotherapeutic agents, including Ara-C, etoposide, vinblastine, or cisplatin. In these
cancer cells in which Mcl-1 degradation is not dependent on the GSK3/phosphodegron-targeted pathway, ERK activation
and Thr 163 phosphorylation are associated with pronounced Mcl-1 stabilization and drug resistance – effects that can be
suppressed by inhibition of ERK activation.
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designed to target the protein, can promote tumor cell death [16–
20].
Mcl-1 was identified based on increased transcription in ML-1
human myeloblastic leukemia cells induced to differentiate upon
exposure to TPA [21,22]. Mcl-1 is also regulated post-translationally (Fig. 1A), as observed in the BL41-3 Burkitt lymphoma cell
line in which endogenous Mcl-1 is amplified and overexpressed
[1,23,24]. Mcl-1 is a PEST protein and is normally subject to
rapid turnover. However, exposure of BL41-3 cells to TPA results
in activation of the mitogen-activated protein (MAP) kinase ERK,

Introduction
Increased expression of Mcl-1, stimulated by growth factors and
other environmental signals, promotes viability and allows the
amplification and function of cell types and lineages needed by the
organism [1–4]. Mcl-1 downregulation, in turn, curbs these
processes and induces death in damaged, nonfunctional, or
senescent cells [1,5–7]. Maintenance of elevated Mcl-1 expression
is associated with drug resistance and poor prognosis in a variety of
cancers [8–15]. Agents that induce Mcl-1 turnover, and inhibitors
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GAPDH (ChemiDoc). All samples were run at the same time and
subjected to the same autoradiographic exposure, where the black
vertical line in this and subsequent figures indicates that lanes have
been rearranged to facilitate comparison. Thr 163 phosphorylation was
also induced by lower concentrations of TPA (e.g., 1 nM; Fig. S1C), and
was inhibited by U0126 (Fig. S1D). m C: BL41-3 cells were either left
untreated or exposed to TPA (1 nM). Some cells were immediately
exposed to CHX to monitor Mcl-1 protein decay on Day 0. Additional
TPA-treated cells were incubated for 24 hours (Day 1 after TPA
Addition) and then exposed to CHX, where a portion of these cells was
retreated with TPA at this time. The untreated cell sample (Time 0) is
identical for each pair of Western blots. The blot at the bottom
confirmed that pERK was reduced at 24 hours.
doi:10.1371/journal.pone.0047060.g001

along with an ERK-dependent increase in Mcl-1 phosphorylation
at Thr 163 and markedly slowed degradation of the Mcl-1 protein
[25,26].
Mcl-1 is also subject to phosphorylation by GSK3 [20,27–34].
In fact, MAP kinase-induced phosphorylation at Thr 163 provides
a priming site for GSK3-induced phosphorylation at Ser 159, as
has been shown in normal mouse fibroblasts exposed to ultraviolet
(UV) irradiation [27]. In this system, phosphorylation at the MAP
kinase phosphorylation site (Thr 163) is carried out by c-Jun Nterminal kinase (JNK); ensuing phosphorylation at the GSK3
phosphorylation site (Ser 159) results in the production of a
phosphodegron that targets Mcl-1 for degradation by E3 ubiquitin
ligases containing F-box proteins [28,32–34]. Mcl-1 can also be
degraded by a variety of other pathways, such as via the BH3containing E3 ubiquitin ligase MULE (also called Arf-BP/Lasu1/
Huwe1 [35,36]), the anaphase promoting complex [37], and
ubiquitin-independent mechanisms [38].
Emerging findings indicate that a reduction in Mcl-1 degradation via the above GSK3-induced pathway contributes to drug
resistance in cancer. For example, GSK3 inactivation in breast
cancer patient samples is associated with abundant Mcl-1
expression and poor outcome [20,32]. Similarly, reduced Mcl-1
degradation via the GSK3/phosphodegron-targeted pathway has
been implicated in chronic lymphocytic leukemia [13,39,40]. A
variety of drug-resistant cancers exhibit inactivation of the F-box
protein FBW7, which lies downstream of phosphorylation events
such as those induced by GSK3 [33,34]. In other cases, cancer
cells exhibit increased expression of a deubiquitinase [41].
Because of the importance of Mcl-1 in cancer, we further
studied the Mcl-1 stabilization that occurs upon TPA-induced
ERK activation in BL41-3 cells. Our purpose was to better
understand the finding that Thr 163 phosphorylation is associated
with Mcl-1 stabilization in these and other cancer cells [42], but
primes Mcl-1 for GSK3/phosphodegron-targeted degradation in
normal fibroblasts [27]. Although phosphorylation at additional
sites could be involved (e.g., Thr 92 [20]), this did not appear to be
the case in BL41-3 cells [25]. The results of our studies showed
that the GSK3-mediated pathway does not play a major role in
Mcl-1 degradation in BL41-3 cells. This contrasts with what is
observed in normal fibroblasts, but parallels the emerging findings
showing that Mcl-1 degradation via this pathway is often impaired
in cancer. The association of Thr 163 phosphorylation with Mcl-1
stabilization in this situation was recapitulated in transfected CHO
cells, where Mcl-1 degradation was not affected by a nonphosphorylatable T163A mutation but was nearly completely
blocked by a phosphomimetic T163E mutation. Along with ERK
activation, Thr 163 phosphorylation, and Mcl-1 stabilization,
TPA-treated BL41-3 cells exhibited markedly increased resistance
to apoptosis-induction upon exposure to chemotherapeutic drugs.
However, drug sensitivity was partially restored by an inhibitor of

Figure 1. TPA-induced ERK activation, Thr 163 phosphorylation, and Mcl-1 stabilization occur rapidly and are subsequently downregulated. A: The phosphorylation sites at Thr 163 and Ser
159 in the human Mcl-1 protein are diagrammed. Thr 163 is subject to
phosphorylation by MAP kinases, as seen upon TPA-induced ERK
activation in BL41-3 cells. Ser 159 is subject to phosphorylation by GSK3.
Mcl-1 is a PEST protein subject to rapid turnover, the half-life of decay
being ,3 hours in BL41-3 cells (stippling of lesser versus greater density
indicates poor PEST and potential PEST sequences; PESTFIND).
However, Mcl-1 exhibits striking stabilization upon TPA-induced ERK
activation and Thr 163 phosphorylation in these cells. Mcl-1 is also
subject to another posttranslational modification involving truncation
of the extreme N-terminus ([28] indicated with an arrowhead). This
results in a closely spaced 42/40 kd doublet, where the lower 40 kd
band lacks ,16 amino acid residues and is the most abundant band
present in BL41-3 cells. The doublet is best visualized on large format
electrophoresis gels (Fig. S1B) but can sometimes be detected on
standard gels (Fig. 1C). As Thr 163 phosphorylation does not prevent Nterminal truncation, Mcl-1 stabilization in the presence of this
phosphorylation is seen as slowed decay of the 40 kd band. B: BL413 cells were either left untreated or exposed to TPA (5 nM) for the
indicated times, and monitored for expression of Thr 163 phosphorylated Mcl-1 (Mcl-1 pT163), total Mcl-1, phosphorylated ERK (pERK), and
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ERK activation. In contrast to normal cells where Thr 163
phosphorylation can promote GSK3/Ser 159 phosphodegrontargeted Mcl-1 degradation and death, in cancer cells in which
Mcl-1 is not degraded through this pathway, ERK activation and
Thr 163 phosphorylation are associated with reduced Mcl-1
degradation and striking drug resistance. Inhibition of ERK
activation/Thr 163 phosphorylation represents a promising
approach for promoting Mcl-1 degradation and drug sensitivity
in these cancer cells.

for 2 hours, and then chased with alphaMEM medium containing
5% FBS and an additional 15 mg/ml L-methionine. After
harvesting and washing twice with PBS on ice, the pellet was
lysed by passage through a syringe in lysis buffer [wash buffer
(142.5 mM KCl, 5 mM MgCl2, 1 mM EGTA in 20 mM Tris-Cl,
pH 7.4) containing 0.2% Nonidet P-40 and Sigma protease and
phosphatase inhibitor cocktails]. The pellet was incubated
overnight in the cold with antiMcl-1 antibody (Santa Cruz S-19)
conjugated to Dynabeads (Dynal, Norway), washed twice with lysis
buffer, once with wash buffer, and subjected to SDS polyacrylamide gel electrophoresis. The gel was fixed in 10% acetic acid:
30% methanol, soaked in NAAMP 100 Amplify (Amersham
Biosciences, UK), dried, and exposed to X-ray film and a
PhosphorImager screen, the latter being analyzed using ImageQuant software.

Methods
Cell Lines and Treatments
BL41-3 cells were derived as a subline of BL41 Burkitt
lymphoma cells as described [23], and were maintained in RPMI
1640 medium containing 7.5% FBS. The 5A-HSmyc CHO cell
derivatives [43,44] were maintained in alphaMEM medium
containing 5% FBS. The mouse AKR-2B embryonic fibroblast
line was from M. J. Getz (Mayo Foundation, Rochester, MN) [45],
and was grown in McCoy’s 5A medium containing 5% FBS. TPA
was from Alexis Biochemicals, LiCl, cycloheximide, LY294002,
etoposide, vinblastine, cis-diamminedichloroplatinum(II) (cisplatin), Wortmannin, and cytosine arabinoside (Ara-C) were from
Sigma, U0126 was from EMD Chemicals, and NaCl from Fisher
Scientific.

Flow Cytometry
Flow cytometry was carried out using an FITC-conjugated
antiMcl-1 antibody with the Caltag Fix&Perm kit (10,000 cells
assayed for each sample).

Cell Death Assays
Apoptotic cells as originally defined morphologically were
scored using Wright’s Giemsa stained cytospin (Shandon) slide
preparations [17,47,48]. PARP cleavage was assayed by Western
blot analysis using the total PARP antibody (Cell Signaling), and
chemiluminescent scanning of the membranes using the ChemiDoc system. Band intensities were quantified using the Fiji
program (NIH ImageJ).

Mcl-1 Constructs and Transfection
Mcl-1 expression constructs were in the pcDNA 3.1 vector [25]
containing a neo resistance marker. The WT-Mcl-1, Mcl-1T163A, and Mcl-1-T162A constructs have been described, and
Mcl-1-T163E and Mcl-1-S159A were prepared using the same
methods [25], with the following primers. For MCL-1-T163E
(upper primer) 59- GGTCACTACCCTCGGAGCCGCCGCCAGCAG-39
and
(lower
primer)
59CTGCTGGCGGCGGCTCCGAGGGTAGTGACC-39,
and
for MCL-1-S159A (upper primer) 59-CGGACGGGGCACTACCCTCGACGCCGCCGC-39 and (lower primer) 59GCGGCGGCGTCGAGGGTAGTGCCCCGTCCG-39. Transfection was carried out with Effectene (Qiagen) or Lipofectectamine 2000 (Invitrogen), using cells plated on the previous day.

Statistical Analysis
The half-life of decay of Mcl-1 encoded proteins (assayed using
the ChemiDoc system) was estimated by non-linear regression
using Prism 5 (GraphPad Software). Other statistical analyses were
carried out using SigmaStat software.

Results
ERK Activation, Thr 163 Phosphorylation, and
Stabilization of the Endogenous Mcl-1 Protein Occur
Early after Exposure of BL41-3 Cells to TPA and are
Subsequently Downregulated

Western Analysis
Western blotting conditions that detect the human Mcl-1
protein have been described [25,43], where no cross-reactivity
with the Chinese hamster protein is seen. Standard size
electrophoresis gels were used except as indicated where large
format gels that separate the Mcl-1 doublet were used. For
monitoring Mcl-1 decay in CHO cells, cells were replated to fresh
medium on the day after transfection and exposed to CHX (20–25
micrograms/ml) 24 hours later [30]. For BL41-3 cells a
concentration of 2.5 micrograms/ml CHX was used [25]. A
ChemiDoc Molecular Imaging system (BioRad) became available
and was used for some experiments, which allowed for estimation
of changes in Mcl-1 expression. These changes were calculated as
a decrease in Mcl-1 expression relative to parallel untreated
control cells. While a useful antibody directed against Mcl-1
phosphoThr 163 is not available commercially, a small amount of
the antibody described previously was available [46].

Pulse/chase

35

BL41-3 cells exhibit abundant constitutive expression of
endogenous Mcl-1 (,5-fold higher than ML-1 cells stimulated
with TPA [23]), and have proven very useful for studies of its
posttranslational regulation. TPA-induced ERK activation results
in little further increase in Mcl-1 expression in these cells (Fig.
S1A, B), unlike in ML-1 and other cells [17,21,22,25,26]. BL41-3
cells are thus particularly useful for studies of TPA/ERK-induced
Thr 163 phosphorylation [24], because effects on the stability of
the protein can be examined in the absence of substantial Mcl-1
induction.
Our initial experiments further characterized the timing of the
effects induced by TPA, since ERK activation is often transient
[17,49]. ERK activation and increased Thr 163 phosphorylation
were detectable within 0.5 hours after TPA addition [24,25] and
maintained for about 6 hours, declining thereafter as monitored
for up to 24 hours (Fig. 1B and Fig. S1A). To determine whether
the decline in ERK activation and Thr 163 phosphorylation seen
following prolonged TPA exposure would be reflected in a decline
in Mcl-1 stabilization, we monitored Mcl-1 decay both immediately after TPA addition and 24 hours later. When CHX was
applied to inhibit protein synthesis, Mcl-1 degradation was near-

S-Met Labeling

Previously described methods were used [24–26]. In brief, one
day after plating, cells were washed 3 times with and incubated in
methionine-free RPMI medium containing 5% dialyzed FBS and
25 mM HEPES buffer. Cells were pulse-labeled with tran-35S-Met
PLOS ONE | www.plosone.org

3

October 2012 | Volume 7 | Issue 10 | e47060

Chemoresistance upon Mcl-1 Thr 163 Phosphorylation

ingly, Thr 163 phosphorylation occurs upon transfection with
WT-Mcl-1, and is not further increased by the addition of TPA
[25]. We therefore set out to examine the effect of a nonphosphorylatable T163A mutation, as well as a phosphomimetic
T163E mutation, upon transfection of mutant constructs into
CHO cells. Interestingly, preliminary results showed that LiCl did
not affect the expression or degradation of WT-Mcl-1 in CHO
cells, although beta-catenin expression was increased (Fig. 3A and
Fig. S2B). This provided a parallel to the findings in endogenously
expressing BL41-3 cells (Fig. 2C), and suggested that Mcl-1
degradation might likewise not be mediated via GSK3 in
transfected CHO cells. In this case, a T163A mutation would
not be expected to affect Mcl-1 degradation. This would differ
from what is seen in normal fibroblasts, where a T163A mutation
slows Mcl-1 degradation because Thr 163 phosphorylation primes
GSK3-induced Ser 159 phosphorylation and degradation [27].
Indeed, the Mcl-1-T163A-encoded protein underwent rapid
degradation upon exposure of transfected CHO cells to CHX
(Fig. 3B), as did the WT-Mcl-1-, Mcl-1-S162A- and Mcl-1-S159Aencoded proteins (Fig. 3B, C). Mcl-1-S162A represents an
additional control as phosphorylation has not been observed at
this site [25]. We note that, as in previous reports [27], an S159A/
T163A double mutant was not examined, because a nearcomplete loss of Mcl-1 phosphorylation is seen with the T163A
mutation in CHO cells [25] and this priming site mutation
prevents Ser 159 phosphorylation in fibroblasts [27]. Taken
together, these results with non-phosphorylatable mutations as
well as LiCl suggest that the GSK3-targeted phosphodegron does
not play a major role in Mcl-1 degradation in transfected CHO
cells. In this situation, the Mcl-1-T163E encoded protein exhibited
striking stabilization [Fig. 3B (see lighter exposure included at the
bottom because of the extensive stabilization seen with this
construct) and Fig. 3C]. Similar results were obtained with AKR2B cells (Fig. 3D).

complete within 7 hours (Fig. 1C, upper left) but was slowed upon
concomitant application of TPA (Fig. 1C, upper right), as in earlier
studies [25]. However, when CHX was applied 24 hours after
TPA, Mcl-1 stabilization was attenuated (Fig. 1C, lower left),
although it could be restored by the application of additional TPA
at this time (Fig. 1C, lower right). In sum, ERK activation, Thr
163 phosphorylation, and Mcl-1 stabilization occur as early events
upon exposure of BL41-3 cells to TPA, and are all subsequently
downregulated. These results reinforced previous findings, which
had suggested a close association between these TPA-induced
effects in that all were inhibited by the ERK pathway inhibitor
U0126 ([25] and Fig. S1D).

Mcl-1 Degradation in BL41-3 Cells is LiCl-insensitive
Mcl-1 can be targeted for degradation by GSK3, and exposure
to TPA results in GSK3 inactivation in some cells
[29,31,32,50,51]. It therefore seemed possible that TPA-induced
GSK3 inactivation and inhibition of Mcl-1 degradation through
this pathway might account for the stabilization seen in BL41-3
cells. As a means of examining this possibility, we probed for an
effect of TPA on expression of the GSK3 target beta-catenin. The
effect of the GSK3 inhibitor LiCl was monitored in parallel. The
latter agent served as a positive control capable of causing an
increase in beta-catenin expression (Fig. 2A lane 3, middle
photograph). Our purpose was to determine whether TPA
mimicked the effect of LiCl to produce an increase in betacatenin expression, as this would be suggestive of an effect on
GSK3. However, TPA did not appear to have such an effect in
that it did not increase beta-catenin expression in the absence of
LiCl (Fig. 2A lane 2, middle photograph).
Mcl-1 expression was also monitored in the above experiment,
and was not found to be increased in the presence of LiCl (Fig. 2A,
upper photograph). In fact, no change in Mcl-1 expression was
seen even at LiCl concentrations that caused a maximal increase
in beta-catenin expression and upon examination using large
format gels (Fig. 2B). This observation was interesting as LiCl
stabilizes Mcl-1 in a variety of cells and we had initially assumed
that a GSK3-mediated, LiCl-sensitive pathway might be involved
in BL41-3 cells. However, further observations were also
consistent with the lack of a role for this pathway in Mcl-1
degradation in BL41-3 cells. Thus, exposure of these cells to
Wortmannin or LY294002, PI3K inhibitors that can prevent
inhibitory phosphorylation of GSK3 and thereby enhance the
degradation of its targets, did not noticeably affect the expression
of Mcl-1 while reducing that of beta-catenin (Fig. S2A). In
addition, LiCl was not found to affect Mcl-1 degradation in the
presence of CHX (Fig. 2C). In sum, Mcl-1 degradation in BL41-3
cells appeared to be largely LiCl-insensitive, and TPA did not act
by mimicking the effect of this GSK3 inhibitor. These results,
taken together with previous findings (Fig. 1 and [25]) suggested
that Thr 163 phosphorylation might be associated with Mcl-1
stabilization in cells in which GSK3-targeted degradation does not
play a major role. This point was considered further below, using
the transfectable CHO cell system in which phosphorylation site
mutants could be examined.

Mcl-1-T163E Exhibits Elevated Accumulation and
Prevents the Outgrowth of Stable G418-resistant
Transfectants
In the above experiment, Mcl-1-T163E exhibited elevated
accumulation during the expression period prior to the application
of CHX (Fig. 3B, time 0). Examination of the time course of
accumulation confirmed that a dramatic increase occurred after
transfection with Mcl-1-T163E as compared to WT-Mcl-1
(Fig. 4A, lanes 4–5 versus lanes 1–2).
Upon pulse/chase metabolic labeling, 35S-Met-Mcl-1-T163E
and 35S-Met-WT-Mcl-1 demonstrated equivalent synthesis during
the initial pulse (Fig. 4B, time 0). After the chase, the decay of 35SMet-Mcl-1-T163E was slowed as compared to that of 35S-MetWT-Mcl-1 (Fig. 4B), although slowing here was not as marked as
had been seen upon monitoring the total Mcl-1-T163E protein by
Western blotting (Fig. 3B). This could reflect the fact that pulse/
chase labeling assays the newly synthesized protein (generally a
fraction of the total), or other differences between these methods
[52,53]. Taken as a whole, the above findings reinforced and
extended those in BL41-3 cells, showing that the T163E mutation
resulted in Mcl-1 stabilization in CHO cells, where degradation
was largely independent of the GSK3-targeted phosphodegron at
S159LPST163P.
The extensive stability and elevated accumulation seen with
Mcl-1-T163E may relate to a further observation, which was that
we were unable to derive stably transfected cell lines with this
construct. This observation was initially somewhat unexpected,
because continuously growing transfected cell lines were previously
obtained with WT-Mcl-1 upon selection with G418 (due to the

Mcl-1 Degradation does not depend on the GSK3targeted Phosphodegron and is Markedly Slowed by a
T163E Mutation in Transfected CHO Cells
CHO cells provide a readily transfectable system useful for
studying mutations at sites found to undergo post-translational
modification endogenously in BL41-3 cells [24,25,30,43]. CHO
cells contain basal activated ERK unlike BL41-3 cells. AccordPLOS ONE | www.plosone.org
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Figure 2. Mcl-1 degradation is insensitive to the GSK3 inhibitor LiCl in BL41-3 cells. A: BL41-3 cells were either left untreated or exposed
to TPA (20 nM) and/or LiCl (20 mM, or NaCl as a control). After 18 hours, expression of Mcl-1, beta-catenin, and GAPDH and was assayed by Western
blotting. Comparable results were observed when the cells were exposed to TPA for 30 minutes instead of 18 hours (not shown). B: BL41-3 cells were
exposed to the indicated concentrations of LiCl (or KCl or NaCl as controls), and assayed for expression of Mcl-1 and beta-catenin after 24 hours. A
large format gel that separates the Mcl-1 doublet bands was used. Slight inhibition of cell growth was seen at 10–20 mM LiCl (13 and 27%,
respectively as compared to 5% with 20 mM NaCl). Results similar to those shown were obtained with an exposure time of 12 hours or a LiCl
concentration of 40 mM (not shown). C: BL41-3 cells were incubated in the absence or presence of LiCl (20 mM) for 0.5 hours, at which time CHX was
applied. Expression of Mcl-1, beta-catenin, and GAPDH was assayed after the indicated times. No substantial difference was seen in parallel cells
exposed to NaCl (20 mM, not shown) instead of LiCl.
doi:10.1371/journal.pone.0047060.g002

neoR marker [43]) and could also be obtained with Mcl-1-T163A.
Mcl-1 expression in these stably transfected cell lines was in the
range seen in cells that express Mcl-1 endogenously, such as BL413 cells and TPA-treated ML-1 cells ([43] and Fig. S3A upper panel
and legend).
In view of the above observation, we examined Mcl-1-T163Etransfected cultures at early times after transfection and selection
with G418. Directly after transfection, a range of Mcl-1 expression
levels was observed (Fig. S3A lower panel). When G418 was then
applied to eliminate untransfected cells, viable cells did not grow
out from Mcl-1-T163E-transfected cultures, unlike what occurred
PLOS ONE | www.plosone.org

with WT-Mcl-1 [Fig. S3B (filled symbols in right versus middle
panel), where cells grew in the absence of G418 in both cases but
lost Mcl-1 expression (open symbols)]. The G418-resistant cells
that grew out with WT-Mcl-1 exhibited much lower levels of
expression than the initial bulk transfected population (Fig. S3C,
lanes 10–12). In contrast, abundant expression was maintained in
Mcl-1-T163E-transfected cultures (Fig. S3C, lanes 16–18). Overall, selection with G418 resulted in the outgrowth of transfectant
lines exhibiting expression in the endogenous range with WT-Mcl1 as well as Mcl-1-T163A, but not with Mcl-1-T163E.
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Figure 3. Mcl-1 degradation is slowed by a T163E mutation (but not T163A) in transfected CHO cells. A: CHO cells were transfected with
WT-Mcl-1 and incubated in the presence of LiCl (+LiCl; 20 mM) or in its absence (2LiCl) where 20 mM NaCl was added in the latter case. After 10
hours, CHX was applied and expression of the introduced WT-Mcl-1 gene product, and endogenous beta-catenin and GAPDH, was assayed after the
indicated times (ChemiDoc). The half-life of Mcl-1 decay was estimated to be ,4 hours in cells exposed to LiCl, and 3.7 hours in the controls exposed
to NaCl. No substantial difference was seen in parallel cells not exposed to NaCl or LiCl. The blot shown is representative of three independent
experiments. B–C: CHO cells were transfected with the indicated constructs, replated on the following day, and incubated for a 24-hour period to
allow expression. CHX was then added and expression of the introduced Mcl-1 gene product and endogenous beta-tubulin was assayed after the
indicated times by Western blotting. In Panel B, the decline in Mcl-1 expression at 3 hours in 2 independent experiments ranged from 53–66% with
WT-Mcl-1, 25–54% with Mcl-1-S162A, and 25–50% with Mcl-1-T163A. While the decline in expression with WT-Mcl-1 appeared be slightly greater than
that seen with Mcl-1-T163A, this was not a consistent finding. A short autoradiographic exposure is also shown because additional bands were
detected at the high levels of expression obtained with Mcl-1-T163E. At the end of the 12-hour observation period, expression of Mcl-1-T163E was
decreased by ,15% in Panel B and ,27% in Panel C, as estimated from short autoradiographic exposures. D: AKR-2B cells transfected with the
indicated constructs were replated on the following day, at which time cell viability (trypan blue dye exclusion) was 88–92% in untransfected as well
as transfected cultures. One day later, cells were exposed to 25 micrograms/ml CHX and assayed after the indicated times for expression of the
introduced Mcl-1 gene product or endogenous actin by Western blotting. Duplicate plates are shown in adjacent lanes.
doi:10.1371/journal.pone.0047060.g003

endogenous range (Fig. S3A upper panel) suggests that such cells
may have had a growth advantage over those with higher levels of
expression. Stable transfectants with another recipient line likewise
exhibited expression in the endogenous range, but not higher [56].
Overall, while WT-Mcl-1 promotes viability in stably transfected
clones expressing levels in the endogenous range, it remains to be

In addition to its antiapoptotic effect, Mcl-1 has been reported
to inhibit cell proliferation in some systems [54,55]. This effect was
not observed in stable transfectants expressing the protein at levels
in the endogenous range [56]. However, inhibition of proliferation
has been seen upon transient transfection or other approaches
capable of producing high levels of expression. The fact that the
WT-Mcl-1-transfected CHO cell lines exhibited expression in the

Figure 4. Slowed degradation without increased synthesis increases Mcl-1 accumulation in the presence of the T163E mutation. A:
CHO cells were co-transfected with either WT-Mcl-1 or Mcl-1-T163E along with pEGFP, and assayed at the indicated times for expression of the
introduced Mcl-1 gene product and EGFP by Western blotting. The rate of increase of the Mcl-1-T163E protein was estimated to be at least 10 times
greater than that of WT-Mcl-1. Approximately equivalent expression of EGFP in WT-Mcl-1- and Mcl-1-T163E-transfected cultures was also seen upon
assay by flow cytometry (not shown). B: CHO cells were transfected with WT-Mcl-1 or Mcl-1-T163E and subjected to a 2-hour pulse exposure to 35SMet, at which time a ‘‘time 0’’ sample was harvested. A chase with medium containing non-radioactive methionine was then performed and the 35SMet-labeled Mcl-1 proteins were assayed after the indicated times (upper photograph). A non-specific band of ,32 kd is included on the figure (*) for
comparative purposes and a separate aliquot of each sample was assayed for total Mcl-1 expression by Western blotting (lower photograph). The
half-life of decay was estimated by PhosphorImager to be ,2.5-fold longer with 35S-Met- Mcl-1-T163E than with 35S-Met-WT-Mcl-1.
doi:10.1371/journal.pone.0047060.g004
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expression (Fig. 5B). There was a close correspondence between
these two effects in that the magnitude of the increase in PARP
cleavage mirrored the decrease in Mcl-1 expression (Fig. 5B and
legend). Since both effects were in evidence at this early time point,
it could not be distinguished whether one or the other might
represent a primary event. In any case, increased apoptosis and
decreased Mcl-1 expression occurred in tandem with a variety of
Ara-C concentrations and at exposure times of 6 or 24 hours, and
both effects were strongly suppressed upon concomitant exposure
to TPA.
We next tested additional chemotherapeutic agents, since Mcl-1
can broadly inhibit the induction of apoptosis [56]. Exposure to
the topoisomerase II inhibitor etoposide, which was previously
found to induce morphologic apoptosis in BL41-3 cells [23],
resulted in PARP cleavage and decreased Mcl-1 expression at 6
hours (Fig. 6A). Both these effects were inhibited in the presence of
TPA. Interestingly, TPA-induced protection from apoptosis, as
well as its effect on Mcl-1 stabilization, were overridden at an
elevated concentration of etoposide (100 micromolar; Fig. 6A, last
lane). Under these conditions, TPA-induced Thr 163 phosphorylation was not in evidence, and PARP cleavage occurred along
with a decrease in Mcl-1 expression.
We also tested the microtubule-disrupting agent vinblastine,
which affects cells in G2/M phase of the cell cycle. Vinblastine can
also cause rapid death (e.g., within hours in ML-1 cells), which is
inhibited in the presence of ERK activation [49]. Exposure of
BL41-3 cells to vinblastine alone for 6 hours resulted in up to
,80% PARP cleavage and an ,80% decrease in Mcl-1
expression (Fig. 6B). These effects were essentially completely
blocked in the presence TPA. In sum, chemotherapeutic drugs
having widely varying modes of action caused a decline in Mcl-1
expression in conjunction with the induction of apoptosis, where
concomitant exposure to TPA suppressed this decline and was
associated with pronounced drug resistance.
In the above experiment with vinblastine, little or no effect was
seen upon 6 hours of exposure in the presence of TPA. This
recalled observations with Ara-C at 6 hours (Fig. 5B), where the
effects of Ara-C were also suppressed by TPA upon 24 hours of
exposure (Fig. 5A). Upon treatment with vinblastine for 24 hours,
PARP cleavage and decreased Mcl-1 expression occurred in the
presence of TPA, but were less marked than in the absence of TPA
(PARP cleavage of ,68% versus .85%, respectively; Fig. S4B).
We also examined PARP cleavage and Mcl-1 expression after 24
hours of exposure to cis-diamminedichloroplatinum(II) (cisplatin),
a DNA-crosslinking agent that acts on cells in the various phases of
the cell cycle. The presence of TPA resulted in inhibition of PARP
cleavage and the maintenance of Mcl-1 expression (Fig. 6C).
These observations were interesting in light of the above finding
that, when TPA is applied by itself, ERK activation, Thr 163
phosphorylation and Mcl-1 stabilization are in decline at 24 hours
(Fig. 1). When TPA is applied in the presence of chemotherapeutic
drugs, it is possible that the maintenance of Mcl-1 expression and
protection from apoptosis at early times (Fig. 5B, and Fig. 6A, B)
means that more cells remain viable upon prolonged exposure.

determined whether higher expression levels result in additional
effects such as inhibition of cell proliferation.
In view of the above considerations, it is perhaps not surprising
that stably transfected lines were not obtained with Mcl-1-T163E.
We note that expression of endogenous tubulin was reduced in
cultures transfected with this construct (Fig. S3C), which could
relate to elevated expression of the transfected protein and/or the
presence of the non-removable Glu mutation. We also note that
some cells within the initial bulk Mcl-1-T163E-transfected
population exhibited lower expression (Fig. S3A lower panel).
Since the Mcl-1-T163E protein accumulates rapidly (Fig. 4A), it is
possible that subsequent ongoing accumulation prevented the
outgrowth of these cells.
We have previously examined the effect of WT-Mcl-1 in cells
that were selected as stable transfectants in G418, and then
derived as clonal transfectant lines [43]. Expression of exogenously
introduced WT-Mcl-1, at levels comparable to those seen
endogenously, resulted in moderate viability-enhancement upon
exposure to apoptosis-inducing stimuli. With this moderate effect
and the variability seen with non-clonal and/or transient
transfectants, obtaining stable transfectant clones was important
for obtaining meaningful results in terms of effects on viability.
The inability to obtain stable transfectants with Mcl-1-T163E thus
precluded meaningful study of its effect on cell viability, a
limitation that will be tackled in the future by deriving inducible
transfectants. In sum, elevated expression was an expected finding
given the stability of Mcl-1-T163E, but prevented the outgrowth
of stable transfectants in which the effects of this mutation could be
further examined. Since elevated accumulation of Mcl-1-T163E
could not be prevented in transfected CHO cells, the effect of Thr
163 phosphorylation was further examined in BL41-3 cells
exposed to TPA.

TPA-induced ERK Activation and Thr 163 Phosphorylation
are Associated with the Maintenance of Mcl-1 Expression
and Increased Chemotherapeutic Drug Resistance in
BL41-3 Cells
Since reduced degradation of Mcl-1 is frequently associated
with drug resistance [33,34,57], we tested for such effects in BL413 cells exposed TPA. This was first examined using Ara-C, an
inhibitor of DNA synthesis previously found to induce morphological apoptosis in BL41-3 cells treated for 24 hours [23]. This
treatment produced morphological apoptosis in about 60% of
cells, along with ,60% Poly ADP ribose polymerase (PARP)
cleavage and a decrease in Mcl-1 expression of ,60% (Fig. 5A
left). Similar effects were seen with Ara-C concentrations of 1–100
micromolar, which may relate to the fact that this agent acts on
cells in S-phase of the cell cycle. These effects were strikingly
reduced (to values of ,20%; Fig. 5A right) when Ara-C was
applied in the presence of TPA to induce ERK activation and Thr
163 phosphorylation. Lower concentrations of Ara-C by itself
resulted in lesser effects on PARP cleavage as well as Mcl-1
expression (Fig. S4A). Here, PARP cleavage with 0.1 micromolar
Ara-C in the absence of TPA was approximately equivalent to that
seen with a 10- to 100-fold higher concentration of Ara-C in the
presence of TPA. In sum, the maintenance of Mcl-1 expression in
the presence of TPA was associated with a $10-fold increase in
resistance to the chemotherapeutic agent.
Morphological apoptosis is seen in BL41-3 cells exposed to AraC for 24 hours but is not readily apparent at 6 hours [23].
However, PARP cleavage can often be detected at early times.
Indeed, exposure to Ara-C by itself for 6 hours resulted in an
increase in PARP cleavage along with a decrease in Mcl-1
PLOS ONE | www.plosone.org

U0126 Partially Restores Chemotherapeutic Drug
Sensitivity in TPA-treated BL41-3 Cells
In a final series of experiments, we preincubated BL41-3 cells
with the ERK pathway inhibitor U0126, prior to exposure to TPA
and chemotherapeutic agents. Our rationale was that U0126
might be expected to inhibit TPA-induced Mcl-1 stabilization
[25], thereby allowing us to determine whether drug sensitivity
and Mcl-1 degradation could be restored. This was first examined
in the presence of Ara-C where PARP cleavage induced by this
8
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Figure 5. Ara-C-induced Mcl-1 degradation and cell death are inhibited upon TPA-induced ERK activation in BL41-3 cells. A: BL41-3
cells were incubated in the absence or presence of TPA (5 nM) for 0.5 hours, followed by the addition of the indicated concentrations of Ara-C. After
24 hours, PARP cleavage and Mcl-1 expression were assayed (ChemiDoc). A representative experiment is included (upper photograph) along with the
average (6 SE) of 5 independent experiments. Also shown for comparative purposes is the percentage of cells exhibiting morphological apoptosis,
assayed with a concentration of 1 nM TPA applied 1 hour before the addition of Ara-C (mean of 3 independent experiments 6 SE run in parallel with
previous studies; some of the BL41-3 cell samples not treated with TPA were included in a previous publication comparing these to BL41 parental
cells (Fig. 4 in reference [23]). *significant difference in the presence of Ara-C as compared to its absence (p,0.05; ANOVA, post-hoc Holm-Sidak test).
B: BL41-3 cells were incubated in the absence or presence of TPA (5 nM) for 0.5 hours, followed by the addition of the indicated concentrations of
Ara-C. After 6 hours, PARP cleavage and Mcl-1 expression were assayed as in Panel A. The average of 4 experiments is shown below representative
blots, where the values for Ara-C concentrations that had similar effects are shown together and overlined. For PARP Cleavage, the SE of the values
shown in successive lanes was 1, 8, 7, 3, and 3, respectively. The Decrease in Mcl-1 Expression was calculated relative to untreated control cells; the SE
of the values shown (other than the untreated control value) was 11, 8, 8, and 7. Linear regression analysis of the Decrease in Mcl-1 Expression versus
PARP Cleavage for 0–10 micromolar Ara-C in the absence of TPA demonstrated an average slope of 1.2 [60.49 (SE) for the 4 experiments)], with an
average r2 value of 0.87.
doi:10.1371/journal.pone.0047060.g005

agent (,50%) is graphed against the decrease Mcl-1 expression
(,50%; Fig. 7A left). These effects were inhibited by TPA, and
partially restored when U0126 was added prior to TPA (to values
of ,45%; Fig. 7A right).
We also examined the effects of increasing concentrations of
etoposide, both to extend the findings above (Fig. 5A) and to assess
the effect of U0126. With etoposide by itself, PARP cleavage and
PLOS ONE | www.plosone.org

decreased Mcl-1 expression occurred approximately in proportion
to each other (Fig. 7B left). The presence of TPA resulted in a
.10-fold increase in resistance to PARP cleavage: whereas a
concentration of 10 micromolar etoposide caused ,50% PARP
cleavage by itself, essentially no effect was seen in the presence of
TPA and, in fact, 100 micromolar etoposide caused only ,33%
PARP cleavage (Fig. 7B middle). When U0126 was added prior to
9
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Figure 6. TPA-induced Mcl-1 stabilization is associated with increased resistance to various chemotherapeutic agents in BL41-3
cells. A: BL41-3 cells were incubated in the absence or presence of TPA (5 nM) for 0.5 hours, followed by the addition of the indicated concentrations
of etoposide. After 6 hours, PARP cleavage, Mcl-1 expression, and Thr 163 phosphorylation were assayed (ChemiDoc), where the values for PARP
Cleavage (%) and the Decrease in Mcl-1 Expression (%) are indicated below the respective blots. B: BL41-3 cells were incubated in the absence or
presence of TPA (5 nM) for 0.5 hours prior to the addition of the indicated concentrations of vinblastine. After 6 hours, PARP cleavage and Mcl-1
expression were assayed as in Panel A. C: BL41-3 cells were incubated in the absence or presence of TPA (5 nM) for 0.5 hours prior to the addition of
the indicated concentrations of cisplatin. After 24 hours, PARP cleavage and Mcl-1 expression were assayed as in Panel A. The blot shown is
representative of 3 independent experiments. The SE of the values shown in successive lanes for PARP Cleavage was 2, 2, 5, 11, 17, 0.2, 4, 2, 3, 4, 6,
and 13, respectively. The Decrease in Mcl-1 Expression was calculated relative to untreated control cells; the SE of the other values shown was 10, 12,
18, 12, 7, 9, and 11.
doi:10.1371/journal.pone.0047060.g006

that TPA-induced maintenance of Mcl-1 expression could be
inhibited by U0126, apoptosis induced by etoposide or Ara-C
could be restored.

TPA, the effects of etoposide on PARP cleavage and Mcl-1
expression were partially restored. Here, a concentration of 10
micromolar etoposide caused ,25% PARP cleavage and an
,25% decrease in Mcl-1 expression, these values being ,60%
with 100 micromolar etoposide. Since both effects were partially
restored, the relationship between Mcl-1 expression and PARP
cleavage in the presence of U0126 plus TPA was virtually identical
to that seen in cells not treated with these agents (i.e., the curves in
Fig. 7B left and right have similar slopes). Overall, to the extent

PLOS ONE | www.plosone.org

Discussion
Mcl-1 is normally subject to rapid up- and downregulation, to
modulate cell viability in response to environmental signals and
maintain tissue homeostasis [1]. Mcl-1 can be targeted for
degradation by several pathways, some of which are regulated
10
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Figure 7. Inhibition of TPA-induced ERK activation partially restores chemotherapy-induced Mcl-1 degradation and cell death. A:
BL41-3 cells were exposed to U0126 (25 micromolar) for 0.5 hours, followed by the addition of TPA (5 nM) for 0.5 hours and then addition of the
indicated concentrations of Ara-C. After 24 hours, PARP cleavage and Mcl-1 expression were assayed (ChemiDoc). The blot shown is representative of
3 independent experiments, where similar effects were seen with the various Ara-C concentrations as above (Fig. 5A). In the graph below the blot, the
Decrease in Mcl-1 Expression (6SE) is plotted against PARP Cleavage (6SE), where points representing the average of cells treated with 1–10 mM
Ara-C are labeled and the unlabeled points represent cells not treated with Ara-C. B: BL41-3 cells were exposed to U0126 (25 micromolar) for 0.5
hours, followed by the addition of TPA (5 nM) for 0.5 hours and then addition of the indicated concentrations of etoposide. After 6 hours, PARP
cleavage and Mcl-1 expression were assayed. The blot shown is representative of 3 independent experiments. The lanes that are overlined on the
Mcl-1 blot represent concentrations of etoposide where U0126 resulted in partial inhibition of Mcl-1 stabilization. In the graph, the average Decrease
in Mcl-1 Expression for each concentration of etoposide (6SE) is plotted against average PARP Cleavage (6SE). The lines shown for No TPA and
U0126+ TPA were determined by linear regression, where the points representing 10 and 100 micromolar etoposide are labeled. The slope of this line
averaged 0.85 in the absence of TPA [60.1 (SE); average r2 of 0.92], and 1.0 in the presence of U0126+ TPA (60.19; average r2 of 0.7).
doi:10.1371/journal.pone.0047060.g007

post-translationally. Phosphorylation at Thr 163 was initially
observed in TPA-treated BL41-3 cells, where it is associated with
Mcl-1 stabilization [25]. Thr 163 phosphorylation also occurs in
UV-irradiated mouse fibroblasts where it primes for GSK3induced Ser 159 phosphorylation and Mcl-1 degradation [27]. In,
the present work, this pathway was not found to play a major role
in Mcl-1 degradation in BL41-3 cells. These cells may thus provide

PLOS ONE | www.plosone.org

a model for the many types of cancer cells that exhibit impaired
Mcl-1 degradation through the GSK3-targeted pathway [20,32].
The finding that Thr 163 phosphorylation can promote Mcl-1
stabilization in this situation in BL41-3 cells was mimicked in
CHO cells transfected with phosphorylation site mutants. Overall,
Thr 163 phosphorylation can prime GSK3-targeted Mcl-1
degradation to promote death in normal cells; however, in cancer
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ERK activation, Thr 163 phosphorylation, and Mcl-1 stabilization
– in the absence of chemotherapeutic drugs - were downregulated
at this time, cell exposed to chemotherapeutic agents for 24 hours
exhibited less apoptosis in the presence (versus the absence) of
TPA. The maintenance of Mcl-1 expression and increased survival
at early times may allow more cells to remain viable upon
prolonged exposure. In terms of patient cancers in which GSK3mediated Mcl-1 degradation is inactive, it remains to be
determined whether the presence of ERK activation/Thr 163
phosphorylation contributes to resistance upon prolonged drug
exposure.
It was also interesting that U0126 partially reversed the
protective effects of TPA. Why reversal was only partial is not
clear, since the inhibitor has been found to be highly effective in
terms of minimizing TPA-induced ERK activation. One possibility is that other ERK-independent effects of TPA play a role, and
another possibility is that some ERK activation occurs in the
presence of U0126. Examination of pERK expression did not
show detectable ERK activation in the presence of U1026 plus
TPA, as in previous studies [25]. However, trace pERK appeared
to be visible in the presence of these two agents plus etoposide (not
shown). In previous studies, we have observed that a modicum of
ERK activation, even if it is transient, can have a noticeable effect
[49]. TPA is a powerful ERK inducer and it remains to be
determined whether some activation, possibly transient, occurs in
the present system. U0126 did not substantially counteract TPAinduced resistance at a low concentration of etoposide (3.3
micromolar), but promoted apoptosis in the presence of higher
etoposide concentrations. In other words, in cancer cells exhibiting
drug resistance in the presence of ERK activation and GSK3
inactivation, an effective approach may involve inhibition of the
effects of ERK along with the application of full doses of
chemotherapeutic agents.
Mcl-1 is highly regulated at multiple levels, and ERK-induced
transcriptional and post-translational mechanisms have been
suggested to act coordinately to rapidly increase or decrease
expression [1]. The present findings lead us to speculate that
coordination may also exist for pathways that degrade the protein.
For example, when Mcl-1 degradation via the GSK3-targeted
phosphodegron is downregulated, such as upon growth factorstimulation [31], ERK-induced Thr 163 phosphorylation may
provide a means for preventing degradation via alternative routes.
This could avert a situation in which the GSK3-targeted pathway
is downregulated, but this does not have a strong impact because
other degradation pathways remain fully operational. In addition,
as the growth stimulus wanes and GSK3 activation increases, the
presence of Thr 163 phosphorylation may prime for ensuing Mcl1 degradation. In other words, this could also provide a
mechanism for preventing overly sustained Mcl-1 expression by
coupling growth factor-induced Mcl-1 stabilization to priming for
subsequent turnover. The interplay between these factors may
then be exploited by cancer cells, where activation of ERK and
inactivation of GSK3/phosphodegron-mediated degradation
would promote extended Mcl-1 stabilization and drug resistance.

cells in which degradation is not dependent on this pathway, ERK
activation and the induction of Thr 163 phosphorylation are
associated with marked Mcl-1 stabilization and chemotherapeutic
drug resistance.
Whereas Thr 163 phosphorylation in BL41-3 cells is induced by
ERK, the priming phosphorylation in mouse fibroblasts is carried
out by JNK, activated upon UV irradiation. Therefore, additional
events induced by JNK may influence GSK3/phosphoSer 159
mediated Mcl-1 degradation in this system. Further studies of nontransformed hematopoietic cell lines may be informative in this
regard. In the latter, Thr 163 phosphorylation is thought to prime
the GSK3-induced Ser 159 phosphorylation/Mcl-1 degradation
that occurs following growth factor deprivation [31]. However,
whether ERK or JNK is involved has not yet been investigated.
Taken together, findings from various systems suggest that MAP
kinase (ERK or JNK)-induced phosphorylation at Thr 163 can
either prime for Mcl-1 degradation – in cells in which this is
targeted by GSK3-induced Ser 159 phosphorylation – or have the
opposite effect to stabilize Mcl-1 in cells in which degradation is
carried out by other, GSK3-independent pathways.
Abundant, dysregulated Mcl-1 expression is an important
determinant of drug resistance in cancer [8,11,20,32,39,58]. This
often involves alterations affecting GSK3-targeted Mcl-1 degradation, such as GSK3 inactivation or changes in downstream
components in the pathway [13,28,32–34,39–41]. However, it is
not clear why reduced Mcl-1 degradation through one pathway
provides a substantial advantage to tumor cells, since multiple
alternative pathways can target Mcl-1 degradation and might be
expected to provide at least partial compensation. In the case of
inactivation of the F-box protein FBW7, for example, Mcl-1
degradation is slowed but still occurs relatively rapidly [33,34].
The present findings provide food for thought in this regard as
they show that – in cells in which Mcl-1 degradation does not
depend on the GSK3/phosphodegron – another common event in
cancer, ERK activation, is associated with Thr 163 phosphorylation, Mcl-1 stabilization, and a dramatic increase in drug
resistance. These findings also point to the importance of future
studies aimed at assessing whether Mcl-1 Thr 163 phosphorylation
could serve as a resistance marker in cancer patients.
The various events induced by TPA in BL41-3 cells appear to
be closely linked. TPA-induced ERK activation, Thr 163
phosphorylation, and Mcl-1 stabilization occur as early, U126inhibitable events and are subsequently downregulated. Similarly,
upon exposure to chemotherapeutic drugs, TPA-induced inhibition of Mcl-1 degradation and apoptosis are seen at early times
and exhibit a close correspondence. Because of this, a cause/effect
relationship between these events could not be distinguished.
Likewise, causality could not be meaningfully addressed via
transfection with Mcl-1-T163E, because the extensive stability of
the mutant protein resulted in its build-up to levels that far
exceeded those seen physiologically. We also note that TPA has a
multitude of effects, and other effects besides ERK activation, Thr
163 phosphorylation, and Mcl-1 stabilization may contribute to
the drug resistance observed in BL41-3 cells. Whatever the case, a
variety of chemotherapeutic drugs, applied at a range of doses,
uniformly caused a decrease in Mcl-1 expression that correlated
with the increase in PARP cleavage (approximately a 1:1
correlation), both events being inhibited upon TPA-induced
ERK activation and Thr 163 phosphorylation. Thus, effects on
Mcl-1 expression may contribute to, and serve as a surrogate
marker for, effects on drug sensitivity/resistance.
A further observation related to those above came out of studies
of TPA-induced viability-protection in cells treated with chemotherapeutic agents for 24 hours. While the direct effects of TPA on
PLOS ONE | www.plosone.org

Supporting Information
Figure S1 Exposure of BL41-3 cells to TPA to activate ERK
stimulates Thr 163 phosphorylation in a fashion that is U0126inhibitable but does not involve a substantial increase in Mcl-1
expression. A: BL41-3 cells were treated with 5 nM TPA and
assayed for expression of Thr 163 phosphorylated Mcl-1 (Mcl-1
pT163), total Mcl-1, GAPDH, and phospho-ERK at the indicated
times by Western blotting (ChemiDoc). B: BL41-3 cells were
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treated with 5 nM TPA and assayed for Mcl-1 expression using a
large format gel that separates the 42/40 kd Mcl-1 doublet bands.
C: BL41-3 cells were treated with the indicated concentrations of
TPA and assayed for expression of Thr 163 phosphorylated Mcl-1,
total Mcl-1, and GAPDH after 1 hour as in Panel A. D: BL41-3
cells were incubated in the absence or presence of U0126 (25 mM)
for 30 minutes, and TPA (5 nM) was then added as indicated for
an additional 3 hours. Expression of Thr 163 phosphorylated Mcl1, total Mcl-1 and GAPDH was assessed as in Panel A. The
asterisk indicates a non-specific band.
(TIF)

or Mcl-1-T163E (in the presence of pEGFP). One day later, cells
were replated in the absence or presence of G418 (600
micrograms/ml; Day 0) as described [43]. On subsequent days,
viable cell number was assayed (trypan blue dye exclusion [53]),
where the symbols represent the total viable cell number in each
culture (filled symbols represent cultures subjected to G418
selection while open symbols represent parallel cultures not
exposed to G418). Viable cells represented a percentage of total
(viable plus dead) cells, and this percentage is shown in
parentheses. This value is shown at the top of the y-axis for cells
examined just prior to G418 addition (day 0 for G418 addition,
the day after the start of transfection). The experiment shown is
representative of 2 independent experiments. C: In the experiment in Panel B, expression of the introduced Mcl-1 gene product
or endogenous tubulin was assayed by Western blotting.
(TIF)

Figure S2 LiCl does not affect Mcl-1 expression in BL41-3 cells
or WT-Mcl-1-transfected CHO cells. A: BL41-3 cells were either
left untreated or exposed to Wortmannin (1 mM) or LiCl (20 mM)
for 18 hours, or to LY294002 (20 mM) for 3 hours, and then
assayed for the expression of Mcl-1, GAPDH, GSK3, and betacatenin, by Western blot. B: CHO cells were transfected with
WT-Mcl-1 and, on the following day, either left untreated or
exposed to LiCl (20 mM) or NaCl (20 mM) and assayed after 18
hours for expression of Mcl-1, beta-catenin, and GAPDH (upper
panel). In another experiment, CHO cells were either left
untreated or exposed to Wortmannin (1 mM) or LiCl (20 mM)
for 18 hours, or to LY294002 (20 mM) for 3 hours, and assayed for
the expression of beta-catenin, GSK3, and GAPDH (lower panel).
(TIF)

Figure S4 TPA-induced Mcl-1 stabilization and increased drug
resistance are maintained after 24 hours of exposure of BL41-3
cells. A: BL41-3 cells were incubated in the absence or presence of
TPA (5 nM) for 0.5 hours prior to the addition of the indicated
concentrations of Ara-C. After 24 hours, PARP cleavage and Mcl1 expression were assayed. B: BL41-3 cells were incubated in the
absence or presence of TPA (5 nM) for 0.5 hours prior to the
addition of the indicated concentrations of vinblastine. After 24
hours, PARP cleavage and Mcl-1 expression were assayed. The
blot shown is representative of 2 independent experiments, where
PARP cleavage was $85% at concentrations of 1–33 micromolar
vinblastine but averaged 68% when TPA was also present.
(TIF)

Figure S3 G418 selection of WT-Mcl-1-, but not Mcl-1-T163E, transfected CHO cells results in the outgrowth of continuous cell
lines exhibiting Mcl-1 expression in the endogenous range. A: In
the upper panel, CHO cells that had been transfected with the
indicated constructs and maintained in G418 for .1 month were
assayed for Mcl-1 expression by flow cytometry with FITCconjugated antiMcl-1. The net mean fluorescence index (MFI) for
the WT-Mcl-1 and Mcl-1-T163A transfectants (black filled
histograms) was 47 and 58, respectively, as compared to values
of 130–133 for BL41-3 cells and a previously described clonal
transfectant line (WT-Mcl-1-Clone 10 [43]. In the lower panel,
CHO cells transfected with Mcl-1-T163E were replated the day
after transfection (when ,80% were viable), and assayed for Mcl-1
expression 24 hours later (black filled histogram). At this time,
,44% of the cell population exhibited Mcl-1 expression, as
estimated by comparison to unstained cells [histograms outlined in
light gray which represent unstained Mcl-1-Clone 10 cells, where
autofluorescence did not differ for the different lines]. B: CHO
cells were either left untransfected or transfected with WT-Mcl-1
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